Corrigendum to "Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431].

ABSTRACT: [This corrects the article DOI: 10.1016/j.jtocrr.2022.100431.].

SUBMITTER: Garassino MC 

PROVIDER: S-EPMC12515734 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature